Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 in Advanced Solid Tumors
NCT03468751Phase 1Unknown
- Sponsor
- Henlix Biotech
- Start
- Feb 2018
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of serplulimab in solid tumor (2 cohorts), sponsored by Henlix Biotech. Primary endpoints: Numbers and percentage of patients with adverse events at 1 year and Maximum tolerated dose of HLX10 at 1 year. Status: unknown.
02
Drugs
serplulimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03468751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468751.